FCF Grants Awarded in 2022
Total grants: 7
- Defining the potential of DNAJB1-PRKACA fusion-specific T cells across human populations — Principal investigator(s): Paul G. Thomas — St. Jude Children's Research Hospital
- Characterization of mitochondria alterations and their functional consequences in fibrolamellar carcinoma (FLC) and FLC-like BAP1 hepatocellular carcinoma — Principal investigator(s): Jessica Zucman-Rossi — Inserm, Paris, France
- Multicenter consortium to define the single-cell activity landscape of fibrolamellar carcinoma — Principal investigator(s): Praveen Sethupathy, Mark Yarchoan, Paul G. Thomas — Cornell University, Johns Hopkins University and St. Jude Children's Research Hospital
- Clinical trial protocol development — Principal investigator(s): Mark Yarchoan — Johns Hopkins University
- Elucidation of nuclear-mitochondrial signaling by DNAJ-PKAc to define targeted vulnerabilities in FLC — Principal investigator(s): Nabeel M. Bardeesy — Massachusetts General Hospital
- Development of a human-derived liver progenitor cell line with DNAJB1-PRKACA fusion gene and characterization of mitochondrial dynamics in fibrolamellar carcinoma — Principal investigator(s): Khashayar Vakili — Boston Children’s Hospital
- Novel synergistic combination therapy in fibrolamellar carcinoma — Principal investigator(s): Sean Ronnekleiv-Kelly — University of Wisconsin
This list represents the complete set of Fibrolamellar Cancer Foundation grants awarded in 2022. The name of the grant is listed, along with the institution receiving the grant and the principal investigator.